Campbell, CA – According to filings with the U.S. Securities and Exchange Commission, Synchron is raising $38,873,462.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Oxley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Synchron

Our mission is to create implantable neural interface technology that improves the human condition. Synchron is bringing bioelectronics to the field of neurovascular medicine and is seeking to address previously untreatable nervous system conditions, without the need for open brain surgery. It is an exciting time for neurointervention. We are creating the field of interventional neuromodulation and neuroprosthetics within the medical subspecialty of interventional neuroradiology. Also known as interventional neurology or endovascular neurosurgery, this specialty comprises physicians trained in neurology, neurosurgery or radiology, and focuses on the use of image-based catheter procedures to deliver technology into the brain and spine.

To learn more about Synchron, visit http://www.synchron.com

Contact:
Thomas Oxley, Chief Executive Officer
917-216-0774
https://www.linkedin.com/in/tomoxl/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved